Published in AIDS Weekly, June 13th, 2005
The filing, when declared effective by the SEC, will allow Vitex, from time to time to offer and sell up to $50 million of equity securities. The terms of any offering made pursuant to this filing will be established at the time of the offering.
The company intends to use the proceeds from the sale of any securities to fund its internal discovery and development programs including the clinical development of its HIV therapeutic drug candidate...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.